Top 5 Drug Type | Count |
---|---|
mRNA vaccine | 50 |
Prophylactic vaccine | 27 |
mRNA | 12 |
Oligonucleotide | 5 |
Personalized antigen vaccine | 2 |
Target- |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date12 Sep 2023 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CA |
First Approval Date03 Nov 2022 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date21 May 2021 |
Start Date10 Apr 2024 |
Sponsor / Collaborator |
Start Date08 Apr 2024 |
Sponsor / Collaborator |
Start Date29 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Andusomeran | COVID-19 More | Approved |
Elasomeran/Imelasomeran ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
Elasomeran/Davesomeran ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
Elasomeran ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
mRNA-1345 ( RSV F protein ) | Respiratory Syncytial Virus Infections More | NDA/BLA |